scholarly journals Peptide-Based Drug-Delivery Systems in Biotechnological Applications: Recent Advances and Perspectives

Molecules ◽  
2019 ◽  
Vol 24 (2) ◽  
pp. 351 ◽  
Author(s):  
Diego Tesauro ◽  
Antonella Accardo ◽  
Carlo Diaferia ◽  
Vittoria Milano ◽  
Jean Guillon ◽  
...  

Peptides of natural and synthetic sources are compounds operating in a wide range of biological interactions. They play a key role in biotechnological applications as both therapeutic and diagnostic tools. They are easily synthesized thanks to solid-phase peptide devices where the amino acid sequence can be exactly selected at molecular levels, by tuning the basic units. Recently, peptides achieved resounding success in drug delivery and in nanomedicine smart applications. These applications are the most significant challenge of recent decades: they can selectively deliver drugs to only pathological tissues whilst saving the other districts of the body. This specific feature allows a reduction in the drug side effects and increases the drug efficacy. In this context, peptide-based aggregates present many advantages, including biocompatibility, high drug loading capacities, chemical diversity, specific targeting, and stimuli responsive drug delivery. A dual behavior is observed: on the one hand they can fulfill a structural and bioactive role. In this review, we focus on the design and the characterization of drug delivery systems using peptide-based carriers; moreover, we will also highlight the peptide ability to self-assemble and to actively address nanosystems toward specific targets.

2017 ◽  
pp. 459-485
Author(s):  
Prabhakar Singh ◽  
Sudhakar Singh ◽  
Rajesh Kumar Kesharwani

In this pharma innovative world, there are more than 30 drug delivery systems. Today's due to lacking the target specificity, the present scenario about drug delivery is emphasizing towards targeted drug delivery systems. Erythrocytes are the most common type of blood cells travel thousands of miles from wide to narrow pathways to deliver oxygen, drugs and nutrient during their lifetime. Red blood cells have strong and targeted potential carrier capabilities for varieties of drugs. Drug-loaded carrier erythrocytes or resealed erythrocytes are promising for various passive and active targeting. Resealed erythrocyte have advantage over several drug carrier models like biocompatibility, biodegradability without toxic products, inert intracellular environment, entrapping potential for a variety of chemicals, protection of the organism against toxic effects of the drug, able to circulate throughout the body, ideal zero-order drug-release kinetics, no undesired immune response against encapsulated drug etc. Resealed erythrocytes are rapidly taken up by macrophages of the Reticuloendothelial System (RES) of the liver, lung, and spleen of the body and hence drugs also. Resealed erythrocytes method of drugs delivery is secure and effective for drugs targeting specially for a longer period of time. This chapter will explain the different method of drug loading for resealed erythrocytes, their characterization, and applications in various therapies and associated health benefits.


Author(s):  
Prabhakar Singh ◽  
Sudhakar Singh ◽  
Rajesh Kumar Kesharwani

In this pharma innovative world, there are more than 30 drug delivery systems. Today's due to lacking the target specificity, the present scenario about drug delivery is emphasizing towards targeted drug delivery systems. Erythrocytes are the most common type of blood cells travel thousands of miles from wide to narrow pathways to deliver oxygen, drugs and nutrient during their lifetime. Red blood cells have strong and targeted potential carrier capabilities for varieties of drugs. Drug-loaded carrier erythrocytes or resealed erythrocytes are promising for various passive and active targeting. Resealed erythrocyte have advantage over several drug carrier models like biocompatibility, biodegradability without toxic products, inert intracellular environment, entrapping potential for a variety of chemicals, protection of the organism against toxic effects of the drug, able to circulate throughout the body, ideal zero-order drug-release kinetics, no undesired immune response against encapsulated drug etc. Resealed erythrocytes are rapidly taken up by macrophages of the Reticuloendothelial System (RES) of the liver, lung, and spleen of the body and hence drugs also. Resealed erythrocytes method of drugs delivery is secure and effective for drugs targeting specially for a longer period of time. This chapter will explain the different method of drug loading for resealed erythrocytes, their characterization, and applications in various therapies and associated health benefits.


Bionatura ◽  
2021 ◽  
Vol 6 (2) ◽  
pp. 1712-1719
Author(s):  
J. Fernanda Romero ◽  
Antonio Díaz-Barrios ◽  
Gema González

The treatment of several diseases requires drugs commonly administered orally or intravenously. Said administration has several drawbacks, such as low control of the necessary drug levels in plasma, making the treatment ineffective and, furthermore, side effects and low compatibility with the patient. Recently, the use of stimuli-responsive hydrogels in controlled Drug Delivery Systems (DDSs) has been considered an excellent alternative because of its inherent biocompatibility, responsiveness to physiological changes in the body, and diversity of both natural and synthetic material options. The present work focuses mainly on the synthesis, characterization, and drug release capacity of poly (N-vinyl caprolactam) (PVCL) and poly (N-vinyl caprolactam) microgels crosslinked with various concentrations of poly (ethylene glycol) diacrylate (PEGDA), which show temperature stimuli-responsiveness near the physiological temperature of the human body. For that reason, changes in the average hydrodynamic particle diameter at different temperatures are estimated and correlated with the drug release rate. The model drug chosen for releasing studies is colchicine, a potential drug for gout disease treatment, currently in disuse because of its low therapeutic index. It is expected that the use of the control release procedure by drug encapsulation in this polymer overcomes this drawback. The synthesis of PVCL homopolymer and three VCL-co-PEGDA hydrogels varying the PEGDA crosslinker concentration was successfully carried out by emulsion polymerization. Their characterization was performed by DLS and FTIR spectroscopy. Polymerization yields were estimated by total solids analysis, and UV-VIS determined the cloud points. Finally, the drug loading and release over time were monitored by HPLC and UV-VIS spectroscopy showing that drug release profiles obtained corresponded to a sustained drug delivery system.


Materials ◽  
2018 ◽  
Vol 12 (1) ◽  
pp. 15 ◽  
Author(s):  
Andreea Madalina Pandele ◽  
Corina Andronescu ◽  
Adi Ghebaur ◽  
Sorina Alexandra Garea ◽  
Horia Iovu

A high number of studies support the use of mesoporous silica nanoparticles (MSN) as carriers for drug delivery systems due to its high biocompatibility both in vitro and in vivo, its large surface area, controlled pore size and, more than this, its good excretion capacity from the body. In this work we attempt to establish the optimal encapsulation parameters of benzalkonium chloride (BZC) into MSN and further study its drug release. The influence of different parameters towards the drug loading in MSN such as pH, contact time and temperature were considered. The adsorption mechanism of the drug has been determined by using the equilibrium data. The modification process was proved using several methods such as Fourier transform-infrared (FT-IR), ultraviolet-visible (UV-VIS), X-ray photoelectron spectroscopy (XPS) and thermogravimetric analysis (TGA). Since MSN shows a lower drug release amount due to the agglomeration tendency, in order to increase MSN dispersion and drug release amount from MSN, two common biocompatible and biodegradable polymers were used as polymer matrix in which the MSN-BZC can be dispersed. The drug release profile of the MSN-BZC and of the synthesized hybrid materials were studied both in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). Polymer-MSN-BZC hybrid materials exhibit a higher drug release percent than the pure MSN-BZC when a higher dispersion is achieved. The dispersion of MSN into the hybrid materials was pointed out in scanning electron microscope (SEM) images. The release mechanism was determined using four mathematic models including first-order, Higuchi, Korsmeyer–Peppas and Weibull.


MRS Bulletin ◽  
1999 ◽  
Vol 24 (5) ◽  
pp. 49-56 ◽  
Author(s):  
M.C. Garnett ◽  
S. Stolnik ◽  
S.E. Dunn ◽  
I. Armstrong ◽  
Wu Lin ◽  
...  

The development of biomaterials to treat, repair, or reconstruct the human body is an increasingly important component of materials research. Collaboration between materials researchers and their industrial and clinical partners is essential for the development of this complex field. To demonstrate the importance of these interactions, two articles in this issue focus on advances in biomaterials relating to the use of colloidal systems for transport, drug delivery, and other medical applications. These articles were coordinated by Dominique Muster (Université Louis Pasteur, Strasbourg) and Franz Burny (Hôpital Erasme, Brussels). The following is the second of these two articles.There are two important objectives in drug delivery research. The first is to maximize the effectiveness of drugs by increasing the amount of drug reaching the target tissue while sparing other tissues the deleterious effects of the drug. The second is to control the release of a drug, so that the period of optimal drug concentration in the target tissue is maximized. A numbe r of different Systems have been investigated to achieve these objectives, including soluble polymeric delivery Systems and a range of colloidal drug delivery forms such as liposomes, emulsions, micelles, microcapsules, microparticles, and nanoparticles. This article focuses on polymeric materials for the production of micro- or nanoparticle Systems for dru g delivery by injection, and their characterization and Performance in vivo.Colloidal particles have a number of advantages as drug delivery Systems; they are easy to prepare, have the potential for high drug loading, and release of the drug can be controlled. However, without surface modification, colloidal particles are difficult to target because they are directed largely to the liver and spieen after intravenous injection. The reasons for this can be found in the context of the body's defenses. In order to protect against disease, the body has a complex System to ensure that invading microorganisms are identified and neutralized at the earliest possible opportunity. Most parasitic or invading organisms which pose a threat are particulate in form, and thus any colloidal drug delivery System will have to evade detection by these mechanisms in order to reach its target.


2019 ◽  
Vol 26 (14) ◽  
pp. 2502-2513 ◽  
Author(s):  
Md. Iqbal Hassan Khan ◽  
Xingye An ◽  
Lei Dai ◽  
Hailong Li ◽  
Avik Khan ◽  
...  

The development of innovative drug delivery systems, versatile to different drug characteristics with better effectiveness and safety, has always been in high demand. Chitosan, an aminopolysaccharide, derived from natural chitin biomass, has received much attention as one of the emerging pharmaceutical excipients and drug delivery entities. Chitosan and its derivatives can be used for direct compression tablets, as disintegrant for controlled release or for improving dissolution. Chitosan has been reported for use in drug delivery system to produce drugs with enhanced muco-adhesiveness, permeation, absorption and bioavailability. Due to filmogenic and ionic properties of chitosan and its derivative(s), drug release mechanism using microsphere technology in hydrogel formulation is particularly relevant to pharmaceutical product development. This review highlights the suitability and future of chitosan in drug delivery with special attention to drug loading and release from chitosan based hydrogels. Extensive studies on the favorable non-toxicity, biocompatibility, biodegradability, solubility and molecular weight variation have made this polymer an attractive candidate for developing novel drug delivery systems including various advanced therapeutic applications such as gene delivery, DNA based drugs, organ specific drug carrier, cancer drug carrier, etc.


2020 ◽  
Vol 26 (33) ◽  
pp. 4174-4184
Author(s):  
Marina P. Abuçafy ◽  
Bruna L. da Silva ◽  
João A. Oshiro-Junior ◽  
Eloisa B. Manaia ◽  
Bruna G. Chiari-Andréo ◽  
...  

Nanoparticles as drug delivery systems and diagnostic agents have gained much attention in recent years, especially for cancer treatment. Nanocarriers improve the therapeutic efficiency and bioavailability of antitumor drugs, besides providing preferential accumulation at the target site. Among different types of nanocarriers for drug delivery assays, metal-organic frameworks (MOFs) have attracted increasing interest in the academic community. MOFs are an emerging class of coordination polymers constructed of metal nodes or clusters and organic linkers that show the capacity to combine a porous structure with high drug loading through distinct kinds of interactions, overcoming the limitations of traditional drug carriers explored up to date. Despite the rational design and synthesis of MOFs, structural aspects and some applications of these materials like gas adsorption have already been comprehensively described in recent years; it is time to demonstrate their potential applications in biomedicine. In this context, MOFs can be used as drug delivery systems and theranostic platforms due to their ability to release drugs and accommodate imaging agents. This review describes the intrinsic characteristics of nanocarriers used in cancer therapy and highlights the latest advances in MOFs as anticancer drug delivery systems and diagnostic agents.


2020 ◽  
Vol 26 (42) ◽  
pp. 5488-5502 ◽  
Author(s):  
Yub Raj Neupane ◽  
Asiya Mahtab ◽  
Lubna Siddiqui ◽  
Archu Singh ◽  
Namrata Gautam ◽  
...  

Autoimmune diseases are collectively addressed as chronic conditions initiated by the loss of one’s immunological tolerance, where the body treats its own cells as foreigners or self-antigens. These hay-wired antibodies or immunologically capable cells lead to a variety of disorders like rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis and recently included neurodegenerative diseases like Alzheimer’s, Parkinsonism and testicular cancer triggered T-cells induced autoimmune response in testes and brain. Conventional treatments for autoimmune diseases possess several downsides due to unfavourable pharmacokinetic behaviour of drug, reflected by low bioavailability, rapid clearance, offsite toxicity, restricted targeting ability and poor therapeutic outcomes. Novel nanovesicular drug delivery systems including liposomes, niosomes, proniosomes, ethosomes, transferosomes, pharmacosomes, ufasomes and biologically originated exosomes have proved to possess alluring prospects in supporting the combat against autoimmune diseases. These nanovesicles have revitalized available treatment modalities as they are biocompatible, biodegradable, less immunogenic and capable of carrying high drug payloads to deliver both hydrophilic as well as lipophilic drugs to specific sites via passive or active targeting. Due to their unique surface chemistry, they can be decorated with physiological or synthetic ligands to target specific receptors overexpressed in different autoimmune diseases and can even cross the blood-brain barrier. This review presents exhaustive yet concise information on the potential of various nanovesicular systems as drug carriers in improving the overall therapeutic efficiency of the dosage regimen for various autoimmune diseases. The role of endogenous exosomes as biomarkers in the diagnosis and prognosis of autoimmune diseases along with monitoring progress of treatment will also be highlighted.


Author(s):  
Smriti Sharma ◽  
Vinayak Bhatia

: In this review nanoscale based drug delivery systems particularly in relevance to the antiglaucoma drugs have been discussed. In addition to that, the latest computational/in silico advances in this field are examined in brief. Using nanoscale materials for drug delivery, is an ideal option to target tumours and drug can be released at areas of the body where traditional drugs may fail to act. Nanoparticles, polymeric nanomaterials, single-wall carbon nanotubes (SWCNTs), quantum dots (QDs), liposomes and graphene are the most important nanomaterials used for drug delivery. Ocular drug delivery is one of the most common and difficult tasks faced by pharmaceutical scientists because of many challenges like circumventing the blood–retinal barrier, corneal epithelium and the blood–aqueous barrier. Authors found compelling empirical evidence of scientists relying on in-silico approaches to develop novel drugs and drug delivery systems for treating glaucoma. This review in nanoscale drug delivery systems will help us in understand the existing queries and evidence gaps and will pave way for effective design of novel ocular drug delivery systems


2018 ◽  
Vol 14 (5) ◽  
pp. 432-439 ◽  
Author(s):  
Juliana M. Juarez ◽  
Jorgelina Cussa ◽  
Marcos B. Gomez Costa ◽  
Oscar A. Anunziata

Background: Controlled drug delivery systems can maintain the concentration of drugs in the exact sites of the body within the optimum range and below the toxicity threshold, improving therapeutic efficacy and reducing toxicity. Mesostructured Cellular Foam (MCF) material is a new promising host for drug delivery systems due to high biocompatibility, in vivo biodegradability and low toxicity. Methods: Ketorolac-Tromethamine/MCF composite was synthesized. The material synthesis and loading of ketorolac-tromethamine into MCF pores were successful as shown by XRD, FTIR, TGA, TEM and textural analyses. Results: We obtained promising results for controlled drug release using the novel MCF material. The application of these materials in KETO release is innovative, achieving an initial high release rate and then maintaining a constant rate at high times. This allows keeping drug concentration within the range of therapeutic efficacy, being highly applicable for the treatment of diseases that need a rapid response. The release of KETO/MCF was compared with other containers of KETO (KETO/SBA-15) and commercial tablets. Conclusion: The best model to fit experimental data was Ritger-Peppas equation. Other models used in this work could not properly explain the controlled drug release of this material. The predominant release of KETO from MCF was non-Fickian diffusion.


Sign in / Sign up

Export Citation Format

Share Document